At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
Ranolazine +1 moredrug
Likely dose
Ranolazine 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI
In Brief
A Phase 4 clinical trial evaluating Ranolazine and Placebo for Pulmonary Hypertension. Completed, enrolled 22 participants across 3 sites.
Detailed Summary
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF \<45%) will improve their health by improving right ventricular (RV) function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, University of Maryland, Gilead Sciences
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedJul 2016
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedJul 12, 2016
Enrollment StartJul 1, 2016
Primary CompletionDec 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago
Interventions
Ranolazinedrug
Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Placebodrug
Placebo by mouth twice per day for a total of 26 weeks